Graphite Bio, Inc.
NNASDAQ:GRPHRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
Company News
Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics
GRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPH
GRAPHITE BIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPH
GRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPH
Shareholder Alert: Ademi LLP investigates whether Graphite Bio, Inc. has obtained a Fair Price in its transaction with LENZ Therapeutics
What Makes Graphite Bio, Inc. (GRPH) a New Buy Stock
GRPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Graphite Bio, Inc. Is Fair to Shareholders
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
Hundreds more tech, biotech layoffs hit Bay Area, Google real estate ally cuts jobs
Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring
Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround
Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting
Graphite Bio: Underfollowed Gene Editing Play At An Attractive Valuation
Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference
Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results
Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?